降低|开年巨献：预防新冠，人类已经有了“三板斧”丨奇点深度( 四 ) 发病率|人类|死亡|口罩|研究

总的来说，虽然新冠病毒已经在人间肆虐了两年多的时间，但是公共卫生措施、新冠疫苗和中和抗体这“三板斧” ，有望帮助人类终结新冠疫情。
参考文献：
[1].Excler J L, Saville M, Berkley S, et al. Vaccine development for emerging infectious diseases[J]. Nature medicine, 2021, 27(4): 591-600.
[2].Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics[J]. The Lancet infectious diseases, 2020, 20(9): e238-e244.
[3].Harrison A G, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis[J]. Trends in immunology, 2020, 41(12): 1100-1115.
[4].Talic S, Shah S, Wild H, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis[J]. bmj, 2021, 375.
[5].Kola L, Kohrt B A, Hanlon C, et al. COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health[J]. The Lancet Psychiatry, 2021, 8(6): 535-550.
[6].Pead P J. Benjamin Jesty: new light in the dawn of vaccination[J]. The Lancet, 2003, 362(9401): 2104-2109.
[7].Pollard A J, Bijker E M. A guide to vaccinology: from basic principles to new developments[J]. Nature Reviews Immunology, 2021, 21(2): 83-100.
[9].陈科达, 李超男, 史丹蓉,等. 新型冠状病毒疫苗的研究进展[J]. 中华临床感染病杂志, 2021, 14(1):8.
[10].Bartsch S M, O'Shea K J, Ferguson M C, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention[J]. American journal of preventive medicine, 2020, 59(4): 493-503.
[11].El Sahly H M, Baden L R, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase[J]. New England Journal of Medicine, 2021, 385(19): 1774-1785.
[12].Thomas S J, Moreira Jr E D, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months[J]. New England Journal of Medicine, 2021, 385(19): 1761-1773.
[15].Heath P T, Galiza E P, Baxter D N, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine[J]. New England Journal of Medicine, 2021, 385(13): 1172-1183.
[16].Tanriover M D, Do?anay H L, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey[J]. The Lancet, 2021, 398(10296): 213-222.
[17].Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial[J]. Jama, 2021, 326(1): 35-45.
[18].Tregoning J S, Flight K E, Higham S L, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape[J]. Nature Reviews Immunology, 2021, 21(10): 626-636.
[19].Lin D Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina[J]. New England Journal of Medicine, 2022.
[20].Wu JT, La J, Branch-Elliman W, et al. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. JAMA Oncol. 2021.
[21].Levin E G, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months[J]. New England Journal of Medicine, 2021.
[22].Dejnirattisai W, Huo J, Zhou D, et al. Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses[J]. 2021.
[24].O’Brien M P, Forleo-Neto E, Musser B J, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19[J]. New England Journal of Medicine, 2021, 385(13): 1184-1195.
[25].https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html
[26].Zhang Y, Hao X, Ma J, et al. Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies[J]. medRxiv, 2021.